Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy

Nuclear Medicine Communications

Volumn 31, Issue 11, 2010, Pages 974-980

  Lin, Wey Yil ^a   Lin, Kun Ju ^a   Weng, Yi Hsin ^a   Yen, Tzu Chen ^a   Shen, Lie Hang ^b   Liao, Mei Hsiu ^b   Lu, Chin Song ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

D2 receptor; dopamine transporter; progressive supranuclear palsy; progressive supranuclear palsy parkinsonism; Richardson's syndrome; single photon emission computer tomography

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; AMANTADINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; IODOBENZAMIDE IODINE 123; LEVODOPA; PERGOLIDE; RADIOPHARMACEUTICAL AGENT; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; MOLECULAR IMAGING; OCCIPITAL CORTEX; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN FUNCTION; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; BENZAMIDES; DIAGNOSIS, DIFFERENTIAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SUPRANUCLEAR PALSY, PROGRESSIVE; SYNAPSES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 77957993386     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833e5f90     Document Type: Article

References (26)

1. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol 2002; 1:359-369.
2. Williams DR, De Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. [see comment]. Brain 2005; 128:1247-1258.
3. Williams DR, Holton JL, Strand C, Pittman A, De Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007; 130:1566-1576.
4. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8:270-279.
5. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002; 17: 303-312.
6. Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm Suppl 2005; 112:677-692.
7. Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 2003; 24:149-150.
8. Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000; 15:1158-1167.
9. Im JH, Chung SJ, Kim JS, Lee MC, Im J-H, Chung SJ, et al. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography. J Neurol Sci 2006; 244:103-109.
10. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57:278-284.
11. Messa C, Volonte MA, Fazio F, Zito F, Carpinelli A, D'Amico A, et al. Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med 1998; 25:1270-1276.
12. Oyanagi C, Katsumi Y, Hanakawa T, Hayashi T, Thuy DD, Hashikawa K, et al. Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography. J Neuroimaging 2002; 12:316-324.
13. Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med 1998; 39:954-960.
14. Arnold G, Schwarz J, Tatsch K, Kraft E, Wachter T, Bandmann O, et al. Steele-Richardson-Olszewski-syndrome: the relation of dopamine D2 receptor binding and subcortical lesions in MRI. J Neural Transm Suppl 2002; 109:503-512.
15. Warren NM, Piggott MA, Greally E, Lake M, Lees AJ, Burn DJ, et al. Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy. Mov Disord 2007; 22:1594-1600.
16. Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, et al. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993;43:S17-S20.
17. Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 1999; 9:545-553.
18. Asenbaum S, Brucke T, Pirker W, Podreka I, Angelberger P,Wenger S, et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 1997; 38:1-6.
19. Bullich S, Cot A, Gallego J, Gunn RN, Suarez M, Pavia J, et al. Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: comparison to 11C-Raclopride PET. Neuroimage 2010; 50:1511-1518.
20. Weng Y-H, Yen T-C, Chen M-C, Kao P-F, Tzen K-Y, Chen R-S, et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med 2004; 45:393-401.
21. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46:231-237.
22. Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord 1998; 13:438-445.
23. Rinne UK, Laihinen A, Rinne JO, Nagren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990; 5:55-59.
24. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]Nmethylspiperone. J Nucl Med 2000; 41:65-70.
25. Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW, Verstappen CCP, et al. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2007; 34:502-507.
26. Spires-Jones TL, Stoothoff WH, De Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 2009; 32:150-159.